Editor-in-Chief: Gian Paolo Andreoletti, MD

Join us on  LinkedIn, Twitter, Facebook, ResearchGate, Doctorsbook, Google Groups, YouTube, SlideShare, Flickr, and share informations and opinions.  Read the Senology.org Newspaperdaily

 

Literature Selection

• Verma S et al.: "Trastuzumab emtansine for HER2-positive advanced breast cancer", N Engl J Med. 2012 Nov 8;367(19):1783-91
• Zagouri F et al.: "Taxanes for Breast Cancer During Pregnancy: A Systematic Review", Clin Breast Cancer. 2012 Nov 1[Epub ahead of print]
• Coopey SB et al.: "The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions", Breast Cancer Res Treat. 2012 Nov 2 [Epub ahead of print]
• Seicean S et al.: "Effect of Statin Therapy on the Risk for Incident Heart Failure in Patients With Breast Cancer Receiving Anthracycline Chemotherapy: An Observational Clinical Cohort Study", J Am Coll Cardiol. 2012 Nov 1 [Epub ahead of print]
• Fakkert IE et al.: "Breast Cancer Incidence After Risk-Reducing Salpingo-Oophorectomy in BRCA1 and BRCA2 Mutation Carriers", Cancer Prev Res (Phila). 2012 Nov;5(11):1291-7
• Domchek SM et al.: "Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer", Cancer. 2012 Nov 16 [Epub ahead of print]
• Vencken PM et al.: "The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers: Implications for counseling", Cancer. 2012 Nov 16 [Epub ahead of print]
• Cott Chubiz JE et al.: "Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers", Cancer. 2012 Nov 26[Epub ahead of print]
• Luo C et al.: "Comparison of Mastoscopic and Conventional Axillary Lymph Node Dissection in Breast Cancer: Long-term Results From a Randomized, Multicenter Trial", Mayo Clin Proc. 2012 Nov 6 [Epub ahead of print]
• Gobardhan PD et al.: "The role of radioactive iodine-125 seed localization in breast-conserving therapy following neoadjuvant chemotherapy", Ann Oncol. 2012 Nov 8. [Epub ahead of print]
• Zuley M et al.: "Digital Breast Tomosynthesis versus Supplemental Diagnostic Mammographic Views for Evaluation of Noncalcified Breast Lesions", Radiology. 2012 Nov 9. [Epub ahead of print]
• D'Orsi CJ et al.: "Stereoscopic Digital Mammography: Improved Specificity and Reduced Rate of Recall in a Prospective Clinical Trial", Radiology. 2012 Nov 13. [Epub ahead of print]
• Brophy JT et al.: "Breast cancer risk in relation to occupations with exposure to carcinogens and endocrine disruptors: a Canadian case--control study", Environ Health. 2012 Nov 19;11(1):87. [Epub ahead of print]

Comment

• "Breast density may be a key discriminator for selecting the optimal screening strategy for women with a family history of breast cancer", Sepideh Saadatmand, Department of Surgery, Erasmus University Medical Centre, Rotterdam, Netherlands

  "To reduce mortality, women with a family history of breast cancer often start mammography screening at a younger age than the general population. Breast density is high in over 50% of women younger than 50 years. High breast density increases breast cancer incidence, but decreases mammography sensitivity. Personalized breast cancer screening might optimize mortality reduction with less over diagnosis. Breast density may be a key discriminator for selecting the optimal screening strategy for women < 55 years with familial breast cancer risk; mammography or MRI. These issues are addressed in a multi-center randomized controlled trial that includes women with a familial risk for breast cancer: the FaMRIsc study. Further information can be found at www.famrisc.nl".
  (Commentary on:  Saadatmand SS et al.: "Breast density as indicator for the use of mammography or MRI to screen women with familial risk for breast cancer (FaMRIsc): a multicentre randomized controlled trial", BMC Cancer. 2012 Oct 2;12(1):440. [Epub ahead of print])

Discussion

  "For patients with ER-positive breast cancer, continuing tamoxifen to 10 years rather stopping at 5 years reduces recurrence and mortality" - Share your opinion on LinkedIn

Questions and Answers 

• Breast Cancer Workshop Summary - with Michael Sabel, Division of Surgical Oncology, University of Michigan Health Systems; Ann Arbor, MI, USA

Fragments of History

• Yale University, USA, 1943: Use of nitrogen mustard in lymphomas (Goodman LS et al., Journal of the American Medical Association) 

Calendar of Events

• Breast-Gynecological International Cancer Congress, January 17-18, 2013, Cairo, Egypt

Literature Selection

• Nielsen SF et al.: "Statin use and reduced cancer-related mortality", N Engl J Med. 2012 Nov 8;367(19):1792-802
• Howell DD et al.: "Single-fraction radiotherapy versus multifraction radiotherapy for palliation of painful vertebral bone metastases-Equivalent efficacy, less toxicity, more convenient: A subset analysis of Radiation Therapy Oncology Group trial 97-14", Cancer. 2012 Nov 16 [Epub ahead of print]
• Kumar S et al.: "Metformin intake is associated with better survival in ovarian cancer: A case-control study", Cancer. 2012 Dec 3 [Epub ahead of print]
• Sonnenberg A et al.: "Helicobacter pylori is a Risk Factor for Colonic Neoplasms", Am J Gastroenterol. 2012 Dec 4 [Epub ahead of print]
• Meyerhardt JA et al.: "Dietary Glycemic Load and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings From CALGB 89803", J Natl Cancer Inst. 2012 Nov 7. [Epub ahead of print]
• Bagshaw PF et al.: "Long-Term Outcomes of the Australasian Randomized Clinical Trial Comparing Laparoscopic and Conventional Open Surgical Treatments for Colon Cancer: The Australasian Laparoscopic Colon Cancer Study Trial", Ann Surg. 2012 Dec;256(6):915-919
• Thelen A. et al.: "Liver resection for hepatocellular carcinoma in patients without cirrhosis", Br J Surg. 2012 Nov 6 [Epub ahead of print]
• Sahasrabuddhe VV et al.: "Nonsteroidal Anti-inflammatory Drug Use, Chronic Liver Disease, and Hepatocellular Carcinoma", J Natl Cancer Inst. 2012 Dec 5;104(23):1808-14
• Wu CY et al.: "Association between nucleoside analogues and risk of hepatitis B virus–related hepatocellular carcinoma recurrence following liver resection", JAMA. 2012 Nov 14;308(18):1906-14
• Flaherty KT et al.: "Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations", N Engl J Med. 2012 Nov;367(18):1694-703
• Teulings HE et al.: "Decreased risk of melanoma and nonmelanoma skin cancer in patients with vitiligo: a survey among 1307 patients and their partners", Br J Dermatol. 2012 Nov 9 [Epub ahead of print]

Questions and Answers 

• Melanoma Workshop Summary - with Keith Flaherty, Massachusetts General Hospital Cancer Center, Boston, MA, USA
• Lung Cancer Workshop Summary - with Ross Camidge, Thoracic Oncology, University of Colorado Cancer Center, Aurora, CO, USA  
• Bladder Cancer Workshop Summary - with Donald Lamm,  University of Arizona, BCG Oncology, Phoenix, AZ, USA  
• Prostate Cancer Workshop Summary 1 and Summary 2 - with David Latini, The Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA, and Sandy Srinivas, Stanford University Medical Center, Stanford, CA, USA

Literature Selection

• Hein A et al.: "Hormone replacement therapy and prognosis in ovarian cancer patients", Eur J Cancer Prev. 2013 Jan;22(1):52-8